Monoclonal Anti-Mage-3 CTL Responses in Melanoma Patients Displaying Tumor Regression After Vaccination With a Recombinant Canarypox Virus

Journal of Immunology - United States
doi 10.4049/jimmunol.171.9.4898
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The American Association of Immunologists

Related search

Correlation Between Tumor Regression and T Cell Responses in Melanoma Patients Vaccinated With a MAGE Antigen

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2004English

The Anti-Tumor Immune Response Induced by a Combination of MAGE-3/MAGE-n-derived Peptides

Oncology Reports
MedicineCancer ResearchOncology
2008English

Intratumoral G100, a TLR4 Agonist, Induces Anti-Tumor Immune Responses and Tumor Regression in Patients With Merkel Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2018English

Safety and Tumor Responses With Lambrolizumab (Anti–PD-1) in Melanoma

New England Journal of Medicine
Medicine
2013English

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2005English

Multispecificity of a Recombinant Anti-Ras Monoclonal Antibody

Journal of Molecular Recognition
Structural BiologyMolecular Biology
2017English

Vaccination With a Recombinant Saccharomyces Cerevisiae Expressing a Tumor Antigen Breaks Immune Tolerance and Elicits Therapeutic Antitumor Responses

Clinical Cancer Research
Cancer ResearchOncology
2008English

P53 as a Target for Cancer Vaccines: Recombinant Canarypox Virus Vectors Expressing P53 Protect Mice Against Lethal Tumor Cell Challenge.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1996English

LAG-3 and PD-1+LAG-3 Inhibition Promote Anti-Tumor Immune Responses in Human Autologous Melanoma/T Cell Co-Cultures

OncoImmunology
OncologyAllergyImmunology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy